152
Participants
Start Date
February 2, 2018
Primary Completion Date
October 2, 2019
Study Completion Date
October 10, 2019
Fulacimstat (BAY1142524)
25 mg BAY1142524 are given twice daily over a treatment period of 6 months
Placebo
Matching placebo tablets are given twice daily over a treatment period of 6 months
Rigshospitalet, Copenhagen
Steno Diabetes Center Copenhagen, Gentofte Municipality
Nordsjællands Hospital, Hillerød
MCOMH Preventsia-2000, Stara Zagora
Med Centre Diamedical 2013, Dimitrovgrad
Med. Center Equita, Varna
Complexo Hospitalario Universitario de Ferrol, Ferrol
The Nazareth Trust Hospital EMMS, Nazareth
Centralsjukhuset Kristianstad, Kristianstad
TAYS TKI Keskus Tutkimusvastaanotto, Tampere
A.O.U. di Padova, Padua
Univ. Alma Mater - Dip. Medicina Spec, Diagnostica e Sperim, Bologna
Hospital de Galdakao, Galdakao
Pihlajalinna ITE Kuopio, Kuopio
IRCCS Casa Sollievo della Sofferenza, Foggia
A.O.U. Policlinico Federico II Napoli, Napoli
Edith Wolfson Medical Center, Holon
DMC - Diabetes Medical Center, Tel Aviv
Shamir Medical Center (Assaf Harofeh), Ẕerifin
Barzilai Medical Center, Ashkelon
Hadassah Hebrew University Hospital Ein Kerem, Jerusalem
Terveystalo Oulu, Oulu
Turun yliopistollinen keskussairaala, kantasairaala, Turku
Hospital Fundació Puigvert, Barcelona
Universitetssjukhuset Örebro, Örebro
Akardo MedSite AB, Stockholm
S3 Clinical Research Centers, Vällingby
Lead Sponsor
Bayer
INDUSTRY